The Trump administration today withdrew a proposed rule that would eliminate the rebate safe harbor for pharmacy benefit managers under the federal anti-kickback statute, and create new safe harbors to protect price reductions at the point-of-sale and certain fees paid by drug makers for PBM services. In comments submitted in April to the Department of Health and Human Services’ Office of Inspector General, AHA said the rule would likely increase premiums for Medicare beneficiaries without addressing the nation’s high and rising drug prices, and urged the agency instead to consider alternative, market-based solutions aimed directly at lowering drug prices. The Campaign for Sustainable Rx Pricing, of which AHA is a founding member, said the rule’s withdrawal will allow the administration and Congress to put greater focus on such solutions.
 

Related News Articles

Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…